Fusion climbs on positive data from tumor treatment trial

Fusion Pharmaceuticals

05/01/2024 12:12

** Shares of drug developer Fusion Pharmaceuticals  FUSN.O 
rise 10.4% to $9.32 premarket
    ** Co said on Thursday that its early-stage trial for the
treatment of solid tumors showed evidence of antitumor activity 
  
    ** FUSN said it also aligned with the U.S. FDA on the
protocol for a mid-stage trial evaluating its treatment for a
type of prostate cancer
    ** Stock more than tripled in 2023

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))